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 “ROLE OF QUANTITATIVE CT IN COPD & ITS 
CORRELATION WITH PULMONARY FUNCTION TEST 
VALUES’’  
 
1. INTRODUCTION 
 
                          Chronic obstructive pulmonary disease (COPD) is a gradually 
progressive disorder characterized by irreversible or partially reversible airway 
obstruction
[1]
. It is predicted to be the fifth leading cause of disability in the world by 
the year 2020
[2]
. The accompanying histopathological changes that lead to air flow 
limitations appear to be a combination of varying degree of parenchymal destruction 
(emphysema), small and large airway changes (bronchiolitis and bronchitis), air 
trapping on expiration, vascular alterations, and chest wall and diaphragmatic 
changes
[3,4]
.  
                        High-resolution computed tomography (HRCT) allows detailed 
anatomical analysis of pulmonary structure, and hence, is currently widely used for 
the detection and characterization of COPD. HRCT has been used to define and 
categorize these patients into two predominant groups – those with 
emphysema-predominant disease and those with airway-predominant disease. The 
former group can be further subclassified based on the type of emphysematous disease 
into centrilobular, panlobular, paraseptal, and bullous emphysema
[5]
. The management 
of COPD is based on on the relative distribution and severity of small airway 
remodelling and loss of elastic recoil. However there maybe variations in the 
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contributions of the individual processes even in patients with similar values of 
pulmonary function tests.  
                       Hence, routine pulmonary function tests are of not much use to assess 
the specific contribution of each pathological process. These changes are better 
evaluated by quantitative computed tomography analysis of the lungs.  
                         Various researchers have shown that CT is of considerable value in 
quantifying the severity of the disease in COPD, either using visual or, more 
preferably, using quantitative CT techniques (QCT). The aim of this prospective study 
was to assess the relationship between the commonly used QCT parameters and 
commonly utilized clinical measures of disease severity in patients with COPD. 
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2. RATIONALE OF STUDY 
 
                The chronic airflow limitation characteristic of COPD is caused by a 
mixture of parenchymal destruction and small airways disease the relative 
contributions of which vary from person to person. The potential usefulness of CT for 
identification of regions of pulmonary emphysema and air trapping has been 
addressed in many investigations
[6]
. Emphysematous changes in the lungs of patients 
with COPD are represented as low attenuation areas on CT images
[7-9]
.  
                 QCT of the lung parenchyma uses accurate measures of lung density to 
generate histogram statistics of the lung to detect lower-density areas of the lung that 
correspond to emphysema on total lung capacity (TLC) scans and can also look at 
lower-density areas of the lung that correspond to air trapping on CT scans of the lung 
obtained at functional residual capacity (FRC) or residual volume(RV). The detection 
of the emphysema is a direct measure of lung remodeling in COPD, and the detection 
of air trapping is believed to be an indirect measure of small airway disease
[10]
. 
                  Standard pulmonary function test results fail to determine the relative 
contribution of the two pathologic processes involved in COPD. However, the degree 
of contribution of the two pathologic processes is clinically important in the planning 
and response to therapeutic intervention
[11]
. For example, pulmonary function may be 
improved by lung volume reduction surgery in patients with emphysema-predominant 
COPD. However, medical treatment may be more effective in cases of airway-
predominant COPD. Computed tomography can also quantitatively assess 
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morphologic changes such as emphysema, hyperinflation, bronchial wall thickening, 
air trapping & vascular pruning. Thus, airway-predominant and emphysema-
predominant COPD can be effectively differentiated by computed tomography
[11,12]
.  
                  The purpose of our study was to determine whether measurements of lung 
attenuation obtained from 3D lung reconstructions at inspiration and expiration reflect 
the severity of COPD. We correlated lung function measurements at inspiration and 
expiration with measurements of lung attenuation on 3D lung reconstructions. We also 
evaluated the relation between the severity of COPD, reflected by Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stage
[1]
, and measurements of lung 
attenuation on 3D lung reconstructions.  
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3.1 EMBRYOLOGY 
 
Anatomically, the respiratory tract is divided into two parts. 
 Upper Respiratory Tract 
 Lower Respiratory Tract 
The nose, nasal cavity & pharynx upper respiratory tract form the upper respiratory 
tract, whereas the larynx, trachea, bronchi & lungs make up the lower respiratory 
tract. 
There are 4 phases of histological development of the lungs. Amniotic fluid, 
respiratory movements & thyroid hormone play an important role in lung maturation 
during late fetal period. One of important processes in lung development is the 
branching of the airways which leads to alveolar saccule formation. Around a total of 
18 to 30 branching generations occur. 
3.1.1 EARLY DEVELOPMENT 
The respiratory diverticulum is a key structure from which the lung bud, also 
referred to as the respiratory bud develops. The respiratory diverticulum forms from 
part of the laryngotracheal tube. The lung bud is an endodermal structure in the 
development of the respiratory tract and gives rise to trachea, larynx bronchi & lungs.  
The respiratory diverticulum
[13]
 grows from the ventral side of the foregut into the 
surrounding mesoderm & forms the lung bud at around the fourth week of 
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development. During the separation of the lung bud from the foregut around the 28
th
 
day of gestation, it forms the trachea & the two bronchial buds, one on each side. 
3.1.2 SEPARATION OF TRACHEA AND ESOPHAGUS 
Initially the trachea is open into the esophagus at its posterior aspect. Later as the lung 
bud elongates two laryngotracheal folds develop, which are longitudinal mesodermal 
ridges, and they gradually grow until they form a wall between the two organs thus 
separating them. 
 
FIGURE 3-1 SEPARATION OF FOREGUT INTO ESOPHAGUS & TRACHEA 
3.1.3 LATER DEVELOPMENT 
A primitive version of the bronchial tree is formed by the growth and branching of the 
primitive lung bud which further determines how the lung lobes will be arranged in 
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the mature organ
[14]
. The pseudoglandular stage is the first stage of alveolar 
development. It occurs between the 5
th
 & 16
th
 weeks of development and it is so 
named because the primitive alveoli histologically resemble glandular tissue at this 
stage. Next the lung enters into canalicular & saccular phases. Two main changes 
occur in these stages. First, the terminal tubes narrow & form small saccules. These 
saccules later make gas exchange possible by association with capillaries. Second, 
type I & type II pneumocytes, are formed by the differentiation of alveolar epithelium. 
It also forms the respiratory epithelium of the trachea & bronchi. 
3.1.4 LUNG DEVELOPMENT STAGES 
 
FIGURE 3-2 LUNG DEVELOPMENT STAGES 
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FIGURE 3-3 LUNG DEVELOPMENT IN A 6 WEEK EMBRYO 
 
 
TABLE 3.1 LUNG DEVELOPMENT STAGES 
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FIGURE 3-4 ADULT CONDUCTING SYSTEM 
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3.2 ANATOMY 
 
The lungs lie within the thoracic cavity separated by the heart & the mediastinum. The 
two lungs are similar, however, they are not completely symmetrical, having different 
number of lobes and different bronchial and vascular anatomy. In most individuals, 
the right lung consists of three lobes which are subdivided into 10 segments and 
the left consists of two lobes and eight segments. The lungs are surrounded by 
the pleura which separates them from the chest wall. The lobes are also incompletely 
separated by fissures. Each lung has an oblique fissure, and a horizontal fissure is also 
seen in the right lung. 
3.2.1 Tracheobronchial tree 
The tracheobronchial tree is a branching structure composed of tubes of an ever-
decreasing diameter which start at the larynx and end in the alveoli. It is broadly 
divided into conduction and respiratory zones. 
3.2.2 Conduction zone 
Gas is warmed and humidified here as it is conducted from the oropharynx to the 
alveoli of the lung where gas exchange occurs. The conduction zone consists of 
the trachea, bronchi, bronchioles and terminal bronchioles. Their function is to 
optimise gas delivery to the alveoli. Their walls contain cilia that remove particulates 
from the inspired gas. They also contain cartilage to ensure that they do not collapse in 
expiration. 
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3.2.3 Respiratory zone 
The respiratory zone is an continuation of the tracheobronchial tree at the terminal 
bronchioles. It is composed of respiratory bronchioles, alveolar ducts, alveoli and it is 
the location of gas transfer within the lung. In any organ, the parenchyma refers the 
functional tissues; thus, the strict definition of lung parenchyma only includes the 
alveoli, alveolar ducts, and respiratory bronchioles.  
3.2.4 Blood supply 
The lungs have dual arterial supply and venous drainage :- pulmonary arteries and 
veins, as well as bronchial arteries and veins 
 Arterial supply 
o pulmonary arteries: They supply de-oxygenated blood from the right ventricle. 
o bronchial arteries: They are branches of the thoracic aorta which supply 
oxygenated blood 
 Venous drainage 
o pulmonary veins: They drain into the left atrium 
o bronchial veins: They drain to the pulmonary veins, superior vena cava, 
and azygos venous system 
3.2.5 Nerve Supply 
Lung function can be controlled externally by innervation of the respiratory 
muscles and diaphragm. However, respiratory function and gas exchange is 
significantly affected by control of the bronchi. For example, 
12 
 
 Sympathetic innervation: noradrenaline causes bronchodilation by acting on 
the beta receptors  
 Parasympathetic innervation: acetylcholine maintains the resting tone of the 
bronchiolar smooth muscle by acting on M-1 muscarinic receptors - this action is 
related to, but distinct from bronchoconstriction 
 other non-autonomic stimuli including carbon dioxide and oxygen tension are also 
involved 
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Figure 3-5 
 
1. Trachea 
2. Right main bronchus 
3. Left main bronchus 
4a. 
4b. 
4c. 
Right upper lobe 
Middle lobe 
Right lower lobe 
5a. 
5b. 
Left upper lobe 
Left lower lobe 
6. Minor fissure 
7. Major fissure 
8. Pulmonary Artery 
3.2.6 Bronchopulmonary Segmental Anatomy 
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Gross Anatomy 
The trachea divides at the carina to form the left and right main stem bronchi which 
then enter the lung substance to divide further. The initial division is into lobar 
bronchi, and subsequent divisions give rise to smaller bronchi and bronchioles till the 
smallest bronchioles connect to alveoli. 
The bronchopulmonary segment is supplied by its own bronchus and artery. Hence 
each segment is functionally and anatomically discrete which allows a single segment 
to be surgically resected without affecting other neighbouring segments. 
Right lung 
The right lung is further subdivided into three lobes with ten segments. The notation 
in brackets refers to the Boyden classification of bronchi. 
 right upper lobe 
o apical segment (B1) 
o posterior segment (B2) 
o anterior segment (B3) 
 right middle lobe 
o lateral segment (B4) 
o medial segment (B5) 
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 right lower lobe 
o superior segment (B6) 
o medial segment (B7) 
o anterior segment (B8) 
o lateral segment (B9) 
o posterior segment (B10) 
Left lung 
The left lung is further subdivided into two lobes and hence, into eight segments. The 
notation in brackets refers to the Boyden classification of bronchi. 
 left upper lobe 
o apicoposterior segment (B1/2) 
o anterior segment (B3) 
o superior lingular segment (B4) 
o inferior lingular segment (B5) 
 left lower lobe 
o superior segment (B6) 
o anteromedial segment (B8) 
o lateral segment (B9) 
o posterior segment (B10) 
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FIGURE 3-6: BRONCHOPULMONARY SEGMENT 
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FIGURE 3-7: RIGHT BRONCHIAL TREE 
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FIGURE 3-8: LEFT BRONCHIAL TREE 
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FIGURE 3-9: CT ANATOMY BRONCHOPULMONARY SEGMENTS 
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3.3 PATHOPHYSIOLOGY & PATHOGENESIS 
 
                       Chronic obstructive pulmonary disease (COPD) is defined as a 
pathologic condition of the lung which is characterized by emphysematous destruction 
of the lung parenchyma as well as remodelling of the small airways. The presence of 
these two processes leads to expiratory airflow obstruction which is not completely 
reversible with the use of inhaled bronchodilators
[15]
. Marked heterogeneity exists in 
subject symptoms and response to therapeutic intervention
[16]
. This inconsistency in 
the association between lung function and disease manifestations has caused 
increasing interest in image based and classification of COPD. 
 
FIGURE 3-10: The two processes involved in COPD 
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3.3.1 Pathogenesis
[17] 
One of the major physiological changes of COPD is airflow limitation. It can occur 
both due to small airway obstruction as well as emphysema. Various factors such as 
hyperplasia and accumulation of cells, mucus and fibrosis lead to narrowing of the 
small airways. Airway fibrosis occurs as a result of Transforming growth factor (TGF-
β) activation. Parenchymal inflammation causes emphysema in the absence of TGF-β 
activation.                 
 The Pathogenesis of emphysema (Fig. 3-10):  
(1) Chronic smoking causes respiratory epithelial damage by recruitment of 
Inflammatory and immune cell within the terminal air spaces of the lung
[18,19] 
  
(2) Elastolytic and other proteinases released by inflammatory cells release damage 
the extracellular matrix of the lung.  
 
(3) Oxidant-induced cigarette smoke damage
[20]
 and senescence directly lead to 
structural cell death (endothelial and epithelial cells)  
 
(4) air space enlargement that defines pulmonary emphysema, occurs as a result of 
ineffective repair of elastin and other extracellular matrix components. 
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FIGURE 3-11: PATHOGENESIS 
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                    Alveoli, small (≤2 mm diameter), & large airways may be affected by 
cigarette smoke. Large airway changes are responsible for cough and sputum, while 
small airways and alveolar damage cause physiologic alterations. In most patients 
with COPD both small airway changes and emphysema are present simultaneously; 
however, there is variation in the contribution of small airway changes & emphysema 
in each patient even with similar pulmonary function test results. 
Large Airway  
                Cigarette smoking causes enlargement of mucus glands and goblet cell 
hyperplasia, which further leads to cough and mucus production. The bronchi also 
develop squamous metaplasia, which causes disruption of muco-ciliary clearance. It is 
also a predisposing factor for carcinogenesis. Airflow limitation may occur as a result 
of bronchial hyperreactivity and smooth muscle hypertrophy. Neutrophil influx in 
upper respiratory tract infections is associated with purulent sputum production.  
Small Airways 
Small airways measuring ≤2 mm diameter are an important cause of airway resistance 
in pathogenesis of COPD
[21]
. Some of the characteristic cellular changes include 
goblet cell metaplasia, replacement of surfactant-secreting Clara cells by mucus-
secreting cells and smooth-muscle hypertrophy. These abnormalities cause fibrosis, 
excess mucus, edema, and cellular infiltration leading to luminal narrowing. Reduced 
surfactant may cause airway narrowing or collapse by increase in surface tension at 
the air-tissue interface. Collection of mononuclear inflammatory cells in distal airway 
tissues cause respiratory bronchioloitis by proteolytic destruction of elastic fibers.  
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3.3.2 Pathophysiology
[22] 
The inflammation of the airways which is a consequence of COPD leads to a series of 
physiological changes.  
 Elastic recoil pressure of the lungs is reduced due to elastin proteolysis. 
 The damage to elastin causes airway narrowing with decreased airflow in 
bronchioles & air trapping. 
 Fixed airway narrowing occurs due to fibrotic remodelling of airways. This 
leads to increased airway resistance that is not reversible by bronchodilators, as 
opposed to the airway resistance in asthma which is reversible by 
bronchodilators. 
 Ventilation perfusion mismatch occurs as a result of apoptosis of bronchial & 
alveolar epithelial cells as well as pulmonary capillaries. The lead to decreased 
surface area of alveoli for gaseous exchange. 
 Elastic recoil pressure of the lung is decreased in emphysema. This leads to a 
decrease in driving pressure for expiration due to loss of support of airways 
which further increases the airway resistance. 
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FIGURE 3-12: Pathophysiological Changes occurring in the Lungs of COPD patients 
Airflow Obstruction 
Fixed airway narrowing occurs due to fibrotic remodelling of airways. This leads to 
increased airway resistance that is not reversible by bronchodilators, as opposed to the 
airway resistance in asthma which is reversible by bronchodilators. 
There is prolongation in the time required for removal of air from lungs during 
expiration as a result of the airway narrowing.  
The airflow obstruction is detected spirometrically by the following factors 
 FEV1  
 FEV1/FVC - less than 0.7 
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Where FEV1 is volume of air removed in first second and FVC is total volume of air 
removed during forceful expiration after maximal inhalation. 
Airflow during forced exhalation is the result of the balance between the elastic recoil 
of the lungs promoting flow and the resistance of the airways limiting flow. In normal 
lungs, as well as in lungs affected by COPD, maximal expiratory flow diminishes as 
the lungs empty because the lung parenchyma provides progressively less elastic 
recoil and because the cross-sectional area of the airways falls, raising the resistance 
to airflow. The decrease in flow coincident with decreased lung volume is readily 
apparent on the expiratory limb of a flow-volume curve.  
 
FIGURE 3-13: PATHOPHYSIOLOGY OF AIRWAY OBSTRUCTION 
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FIGURE 3-14: PATHOPHYSIOLOGY OF AIRWAY OBSTRUCTION 
Hyperinflation 
Lung hyperinflation occurs as a result of air trapping in COPD. It is the primary cause 
of dyspnoea in COPD patients & produces barrel shaped chest.  
 
FIGURE 3-15: PATHOPHYSIOLOGY OF DYNAMIC HYPERINFLATION IN 
COPD 
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Pulmonary Hypertension 
There is increased pulmonary vascular resistance as a result of endothelial 
dysfunction, hypertrophy of pulmonary capillary musculature, intimal thickening & 
apoptosis which are initiated by the structural changes in COPD. This results in 
predisposition to pulmonary arterial hypertension. In severe cases it may lead to right 
heart failure. 
 
FIGURE 3-16: PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION IN 
COPD 
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3.3.3 Risk Factors
[23]
: 
The most common cause is cigarette smoking. It takes many years of smoking to 
develop COPD and as such typically patients are older adults. There are, however, a 
number of other less common risk factors. They include: 
 industrial exposure (e.g. mining) 
 cystic fibrosis 
 alpha-1 antitrypsin deficiency 
 intravenous drug use 
 immune deficiency syndromes 
 vasculitides and connective tissue disorders 
3.3.4 Clinical Features: 
Symptoms of COPD include  
 dyspnoea on exertion,  
 wheezing,  
 productive cough,  
 pursed-lip breathing, and  
 use of accessory muscles.  
Patients with chronic bronchitis are classically "blue bloaters," while those with 
emphysema are known as "pink puffers". In advanced cases, muscle 
wasting, asterixis, and peripheral oedema may be seen. 
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3.3.5 Pulmonary Function Tests (PFT): 
GOLD 
STAGE
[1] 
SEVERITY SPIROMETRY 
I Mild FEV1/FVC <0.7 and FEV1 ≥80% predicted 
II Moderate FEV1/FVC <0.7 and FEV1 ≥50% but <80% 
predicted 
I Severe FEV1/FVC <0.7 and FEV1 ≥30% but <50% 
predicted 
IV Very Severe FEV1/FVC <0.7 and FEV1 <30% predicted 
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3.4 REVIEW OF LITERATURE 
3.4.1 EMPHYSEMA  
Emphysematous lung destruction results in replacement of normal lung (which has a 
typical attenuation about -850 HU on inspiratory CT) by air-containing spaces, with 
CT attenuation close to -1000 HU. Emphysema may be further classified as 
panlobular, centrilobular, or paraseptal
[24]
.  
IMAGING FEATURES
[25-27] 
CT FINDINGS
[28] 
Centrilobular emphysema 
 commonest type of emphysema encountered in imaging. 
 predominantly occurs in the upper zones of each lobe [29]. 
 appears as focal lucencies measuring up to 1 cm in diameter, around the central 
respiratory bronchioles. 
 located centrally within the secondary pulmonary lobule. 
 Strongly associated with smoking. 
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FIGURE 3-17: CENTRILOBULAR EMPHYSEMA 
 
 
 
FIGURE 3-18: CENTRILOBULAR EMPHYSEMA 
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Panlobular emphysema
[30] 
 widespread areas of abnormally low attenuation due to widespread destruction 
of entire secondary pulmonary lobule. 
 affected lung shows appear fewer and smaller pulmonary vessels than normal. 
 Commonly seen in association with alpha1-antitrypsine deficiency. 
 Findings are more predominant in the lower lobes. 
 
 
 
FIGURE 3-19: PANLOBULAR EMPHYSEMA 
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FIGURE 3-20: PANLOBULAR EMPHYSEMA 
Paraseptal emphysema
[31,32] 
 localized near fissures and pleura  
 commonly associated with bullae formation  
 Is a cause of spontaneous pneumothorax in young adults. 
 
FIGURE 3-21: PARASEPTAL EMPHYSEMA 
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FIGURE 3-22: PARASEPTAL EMPHYSEMA 
QUANTITATIVE CT
[33-37]
 
 Emphysema is quantitatively assessed by the following parameters :-  
 Relative areas of low-attenuation lower than a predetermined threshold  
 The frequency-attenuation distribution percentile.  
There is good correlation of PFT and low-attenuation regions consisting of pixels with 
attenuation values of −950 HU or less on thin-section CT scans. 
3.4.2 SMALL AIRWAY DISEASE:  
Chronic exposure to cigarette smoke damages the airway, leading to remodeling with 
epithelial cell hyperplasia, smooth muscle hypertrophy, and mucous metaplasia. 
Mucous metaplasia is considered the most significant contributor to airflow 
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obstruction
[38,39]
. Smooth muscle hypertrophy and airway wall fibrosis are other 
pathologic features that may be found in patients with COPD
[40,41]
. The mechanisms of 
airflow obstruction include increased mucus secretion with resultant luminal 
occlusion, epithelial layer thickening that encroaches on the airway lumen
[42]
, and 
increased mucus secretion with altered airway surface tension and a resultant 
predisposition to expiratory collapse
[43]
.  
IMAGING FEATURES 
Small airway disease cannot be visualized directly with current radiographic 
techniques.  
 
FIGURE 3-23: Small airway disease causing air trapping on CT 
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CT 
 Direct Signs 
o thickened peripheral airways: may only be seen in the proximal portion 
 Indirect Signs  
o air trapping  
o subsegmental atelectasis  
o mosaic lung attenuation  
o centrilobular nodules  
o tree-in-bud changes  
QUANTITATIVE CT
[44] 
Studies show that pulmonary densitometry parameters calculated on the basis of 
expiratory CT scans or paired inspiratory and expiratory CT scans allow the indirect 
evaluation of airway obstruction in patients with various types of obstructive lung 
disease
[45-49]
.These quantitative methods are based on the depiction of air trapping as 
regions of abnormal pulmonary lucency. Consequently, the degree of change in lung 
attenuation values after expiration has been quantified by using densitometric 
parameters such as change between inspiratory and expiratory CT scanning in the 
proportion of the lung volume with a particular attenuation value, or the ratio of mean 
lung attenuation at expiratory CT to mean lung attenuation at inspiratory CT
[47-49]
. The 
relative low-attenuation area (ie, the area with attenuation below a specific threshold 
value) measured at expiratory CT correlates more closely with the severity of airway 
obstruction than does that measured at inspiratory CT
[45-48]
. Several studies have 
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shown a significant correlation between the expiratory-inspiratory attenuation ratio 
and airflow limitation in COPD
[49-51]
. 
3.4.3 LARGE AIRWAY DISEASE:  
Coughing and sputum production are clinical manifestations of chronic bronchitis. At 
pathologic examination, hypertrophy of the bronchial wall mucous glands is seen in 
association with chronic inflammation and fibrous replacement of the smooth muscle 
layer. Those pathologic changes result in bronchial wall thickening and narrowing of 
the bronchial lumen. In patients with COPD, bronchial wall thickening can be 
evaluated qualitatively and quantitatively at CT
[52-55]
. The correlation of airway 
measurements with lung function varies according to the order of bronchial 
generation. Thus, when airway dimensions are evaluated, bronchial generation– based 
analysis should be considered. 
3.4.4 VASCULAR ALTERATIONS  
Pulmonary vascular alteration is a characteristic feature of COPD. Narrowing and 
numeric reduction of small pulmonary arteries can be observed in patients with severe 
COPD
[56]
. Typically, passive vascular compression due to emphysema and hypoxic 
vasoconstriction has been considered the major manifestation of vascular alteration in 
COPD. However, pulmonary vascular alterations are not exclusive to advanced-stage 
COPD but also have been found in mild COPD and in smokers with normal 
pulmonary function
[57,58]
. Vascular alterations in COPD may include increased 
thickness of the intima because of smooth muscle cell proliferation, increased elastin, 
and collagen deposition. Recent studies suggest that both pulmonary and 
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extrapulmonary vascular alterations in patients with COPD are closely related to 
endothelial dysfunction
[59-61]
. Endothelial dysfunction results from changes in the 
expression and release of vasoactive mediators. In particular, vascular endothelial 
growth factor (VEGF) plays an important role in the pathogenesis of both vascular 
alteration and emphysema
[60-62]
. Kanazawa et al
[63]
 reported that the VEGF level in 
induced sputum from patients with emphysema is decreased in comparison with that 
from patients with chronic bronchitis. Vascular alterations also may be relevant to the 
diagnosis and characterization of COPD. 
 
FIGURE 3-24: Pathogenesis of Cor Pulmonale in COPD 
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3.4.5 OTHER STUDIES: 
1. Bankier et al.[35] - QCT measurements correlated better with macroscopic 
measurements of emphysema than visual CT scoring. 
 
2. Madani et al.[66] - the best correlation between QCT and macroscopic and 
microscopic measures of emphysema was obtained using a density mask 
technique with a threshold level of –960 or –970 HU, although the correlation 
for a threshold of –950 HU was almost as high. 
 
3. Dirksen et al.[67] - use of CT will provide an analysis of change in lung density 
over time that is more sensitive to intervention than the usual analysis of 
change in lung function (FEV1) 
 
4. Hasegawa et al.[68] - measurements of the bronchial wall area and inner 
luminal area obtained in distal (small) airways were more closely correlated 
with the percentage of predicted FEV1 than those obtained in proximal (large) 
airways. These findings may indicate that airflow limitation is more closely 
related to the dimensions of the small airways than to those of the large 
airways.  
 
5. Park et al.[69] - moderate-to-high correlation was found between the percentage 
of lung volume occupied by attenuation values lower than three thresholds (-
900 HU, -910 HU, -950 HU) percentage volumes and TLC,FEV1 and 
FEV1/FVC, and PFT. 
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6. Knudson et al.[70]  - CT obtained in expiration shows stronger correlation in 
the assessment of emphysema the CT obtained during inspiration.  
 
7. Fujimoto et al[71] studied the relationship between morphologic changes of 
COPD evaluated visually at CT and the clinical features of COPD and 
identified three COPD phenotypes: phenotype A, characterized by no or 
minimal emphysema with or without bronchial wall thickening; phenotype E, 
characterized by emphysema without bronchial wall thickening; and phenotype 
M, characterized by emphysema with bronchial wall thickening. They found 
that patients with phenotype M disease, in comparison with those with 
phenotype E disease, showed a significant increase in the percentage of 
predicted FEV1 in response to treatment with bronchodilators. On the basis of 
this finding, they speculated that airflow limitation in patients with phenotype 
M disease was caused by intrinsic small airway remodeling, whereas that in 
patients with phenotype E disease was caused by decreased elastic recoil. If 
this conclusion is valid, then the presence of airway wall thickening can be 
used to determine the cause of airflow limitation in patients with COPD and 
emphysema, and, furthermore, COPD cannot be classified according to the 
extent of emphysema alone but only by considering that parameter in 
combination with others, including airway dimensions. 
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COPD Phenotype 
Emphysema 
(%Low 
Attenuation Area) 
Airway Wall 
Thickening 
Air Trapping 
(Residual 
Volume) 
Emphysema-
predominant 
Moderate to severe None to mild None to mild 
Airway-predominant 
None to mild 
Moderate to 
severe 
Moderate to 
severe 
Mixed    
 More small airway 
remodeling than 
emphysema 
Moderate to severe 
Moderate to 
severe 
Moderate to 
severe 
 More emphysema than 
small airway 
remodeling 
Moderate to severe 
Moderate to 
severe 
None to mild 
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MATERIALS AND METHODS 
4.1 AIM OF THE STUDY: 
1. Primary Aim - To assess the role of Quantitative CT in COPD   
2. Secondary Aim - To evaluate the relationship between Quantitative CT(QCT) 
and spirometric measurements of disease severity in subjects with and without 
chronic obstructive pulmonary disease (COPD). 
4.2 STUDY AREA:  
Barnard Institute of Radiology, Madras Medical College, Chennai. 
4.3 STUDY PERIOD:  
1 year (July 2017 to July 2018) 
4.4 SAMPLE SIZE:  70 
4.5 STUDY DESIGN: Prospective Comparative Study 
4.6 INCLUSION CRITERIA: 
Cases: Eligible subjects between the ages of 40 and 65 years & having COPD.  
Controls: Subjects between the ages of 40 and 65 years & not having COPD. 
4.7 EXCLUSION CRITERIA: 
 Subjects with concomitant respiratory disorders other than COPD. 
 Non-Cooperative patients 
 COPD patients who are unable to hold their breath for sufficient period of time 
to allow for examination. 
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4.8 METHODOLOGY: 
This prospective study was performed after obtaining clearance from our Institutional 
Ethics Committee and institutional informed consent guidelines were observed. 
4.9 STUDY POPULATION: 
Patients referred from Thoracic Medicine department for CT chest who were proved 
to have COPD by Pulmonary Function Test were included in this study during the 
period from July 2017 to July 2018. 
Controls were subjects with normal Pulmonary Function Test values & normal CT 
chest findings who were referred for reasons other than COPD. 
The patients were screened using the drawn inclusion/ exclusion criteria. Relevant 
entries in the proforma for each patient were made after reviewing his/her case sheet 
& previous medical records. 
QCT data were suppressed from the cohort if scans showed extreme motion or had 
other technical inadequacies (e.g., non-protocol reconstruction kernel, low exposure, 
or a value of > 1 for the ratio of functional residual capacity [FRC] to total lung 
capacity [TLC]).  
The resultant dataset consists of a total of 70 subjects: 21 subjects without COPD (no 
spirometric evidence of airway obstruction) who served as control, 6 subjects with 
GOLD stage 1 disease (12%), 18 subjects with GOLD stage 2 disease (37%), 13 
subjects with GOLD stage 3 disease (27%), and 12 subjects with GOLD stage 4 
disease (24%). The cohort consists of 57 men (81%) and 13 women (19%). 
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All patients were required to provide written informed consent before study 
participation. 
4.10 CT EXAMINATION: 
All the Quantitative CT studies were performed in a 16 slice CT scanner (TOSHIBA-
ALEXION).   
In each case, CT of the thorax was performed from the lung apices through the level 
of the adrenal glands. These scans were reconstructed with a slice thickness of 1 mm 
and corresponding slice interval of 1mm, to achieve near-isotropic voxels. 
Inspiratory & expiratory scans were acquired at 100 mAs; all scans were acquired at 
120 kVp. CT dose modulation and IV contrast agents were not used for this study. 
Scanning was performed as follows: 
 Inspiratory CT – Subject was asked to take a deep breath & plain CT chest was 
taken at full inspiration to obtain Total Lung Capacity. 
 Expiratory CT – Subject was asked to hold breath in normal expiration & CT 
chest was taken to obtain Functional Residual Capacity. 
 
4.11 IMAGE POSTPROCESSING & ANALYSIS 
Three-dimensional models of the lungs were reconstructed with analysis software 
(TOSHIBA lung Analysis Software). In this software, areas of low attenuation (HU 
threshold set as -950 for inspiratory CT & -856 for expiratory CT) are highlighted in 
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yellow. Lung volume, low attenuation volume, low attenuation percentage and mean 
lung attenuation were calculated. 
Inner & outer diameters measured manually in anterior segmental bronchus of 
bilateral upper lobes (4
th
 generation bronchi) and their average value was taken. Wall 
area & wall thickness were calculated manually. 
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CASE 1  
51 year old male, smoker for 20 years, stopped for past 4 years. Diagnosed to have 
COPD GOLD stage 1 by PFT. 
FEV1 – 1.33 
FVC – 1.84 
FEV1/FVC – 0.72 
QUANTITATIVE CT: 
Inspiration 
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Expiration: 
 
 
 
PARAMETERS VALUES 
% lung attenuation <-950HU 5.4 
Mean lung attenuation in Inspiration -843 HU 
Total Lung Capacity 5.3 L 
% lung attenuation <-856HU 25.3 
Mean lung attenuation in Expiration -733 HU 
Functional Residual Capacity 3.1 L 
Inner Diameter 3.6mm 
Airway Wall Thickness 1.4mm 
Inner Area 7.5mm
3 
Outer Area 32.1mm
3 
Wall Area 24.6mm
3 
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CASE 2 
57 year old male, smoker for 35 years. Diagnosed to have COPD GOLD stage 2 by 
PFT. 
FEV1 – 1.05 
FVC – 1.94 
FEV1/FVC – 0.54 
QUANTITATIVE CT: 
Inspiration 
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Expiration 
 
 
 
PARAMETERS VALUES 
% lung attenuation <-950HU 12.3 
Mean lung attenuation in Inspiration -878 HU 
Total Lung Capacity 5.5 L 
% lung attenuation <-856HU 39.4 
Mean lung attenuation in Expiration -764 HU 
Functional Residual Capacity 3.3 L 
Inner Diameter 3.4mm 
Airway Wall Thickness 1.3mm 
Inner Area 9mm
3
 
Outer Area 28.3mm
3
 
Wall Area 19.3mm
3
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CASE 3 
50 year old male, smoker for 28 years. Diagnosed to have COPD GOLD stage 3 by 
PFT. 
FEV1 – 0.82 
FVC – 1.51 
FEV1/FVC – 0.54 
QUANTITATIVE CT: 
Inspiration 
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Expiration 
 
 
PARAMETERS VALUES 
% lung attenuation <-950HU 16.7 
Mean lung attenuation in Inspiration -878 HU 
Total Lung Capacity 5.7 L 
% lung attenuation <-856HU 48.6 
Mean lung attenuation in Expiration -817 HU 
Functional Residual Capacity 3.5 L 
Inner Diameter 3.1mm 
Airway Wall Thickness 1.5mm 
Inner Area 7.5mm
3
 
Outer Area 39.2mm
3
 
Wall Area 21.7mm
3
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CASE 4 
 
60 year old male, smoker for 45 years. Diagnosed to have COPD GOLD stage 4 by 
PFT. 
FEV1 – 0.62 
FVC – 0.88 
FEV1/FVC – 0.7 
QUANTITATIVE CT: 
Inspiration 
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Expiration 
 
 
PARAMETERS VALUES 
% lung attenuation <-950HU 29.3 
Mean lung attenuation in Inspiration -890 HU 
Total Lung Capacity 5.9 L 
% lung attenuation <-856HU 65.2 
Mean lung attenuation in Expiration -850 HU 
Functional Residual Capacity 4.1 L 
Inner Diameter 2.7mm 
Airway Wall Thickness 1.6mm 
Inner Area 5.7mm
3
 
Outer Area 27.3mm
3
 
Wall Area 21.6mm
3
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CASE 5 
41 year old male, smoker for 10 years. No other complaints. 
PFT: 
FEV1 – 3.3 
FVC - 4.1 
FEV1/FVC – 0.8 
QUANTITATIVE CT 
Inspiration 
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Expiration 
 
 
PARAMETERS VALUES 
% lung attenuation <-950HU 0 
Mean lung attenuation in Inspiration -813 HU 
Total Lung Capacity 4.9 L 
% lung attenuation <-856HU 0 
Mean lung attenuation in Expiration -695 HU 
Functional Residual Capacity 2.8 L 
Inner Diameter 4.2mm 
Airway Wall Thickness 1.2mm 
Inner Area 13.8mm
3
 
Outer Area 34.2mm
3
 
Wall Area 20.4mm
3
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6. STATISTICAL ANALYSIS 
 
 The collected data were analysed with IBM.SPSS statistics software 23.0 
Version. 
 To describe about the data descriptive statistics frequency analysis, percentage 
analysis were used for categorical variables and the mean & S.D were used for 
continuous variables.  
 To find the significant difference between the bivariate samples in Independent 
groups the Unpaired sample t-test was used.  
 For the multivariate analysis the one way ANOVA with Tukey's Post-Hoc test 
was used. 
 To assess the relationship between the variables Pearson's Correlation was used 
with Scatter plot. 
 To identify the influence of the variables the multiple regression model with 
enter method. 
 To find the significance in categorical data Chi-Square test was used similarly 
if the expected cell frequency is less than 5 in 2×2 tables then the Fisher's Exact 
was used.   
 In all the above statistical tools the probability value .05 is considered as 
significant level (significant, not significant)  
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7. OBSERVATION & RESULTS 
 
7.1 FREQUENCY TABLES: 
7.1.1 AGE 
 
TABLE 7.1 AGE WISE DESTRIBUTION IN STUDY GROUP 
AGE (yrs) 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 40 - 49 yrs 32 45.7 45.7 45.7 
50 - 59 yrs 31 44.3 44.3 90.0 
60 - 69 yrs 7 10.0 10.0 100.0 
Total 70 100.0 100.0   
 
FIGURE 7.1 BAR DIAGRAM SHOWING AGE WISE DESTRIBUTION IN 
STUDY GROUP 
 
 
7.1.2 SEX 
 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
50.0
40 - 49 yrs 50 - 59 yrs 60 - 69 yrs
Age range % 
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TABLE 7.2 SEX DESTRIBUTION IN STUDY GROUP 
SEX 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Female 13 18.6 18.6 18.6 
Male 57 81.4 81.4 100.0 
Total 70 100.0 100.0   
 
 
FIGURE 7.2 PIE CHART SHOWING SEX DESTRIBUTION IN STUDY 
GROUP 
 
 
        
 
 
 
 
 
 
 
19% 
81% 
Gender distribution 
Female Male
60 
 
7.1.3 GOLD STAGE 
 
TABLE 7.3 GOLD STAGE DESTRIBUTION IN STUDY GROUP 
GOLD STAGE 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid I 6 8.6 12.2 12.2 
II 18 25.7 36.7 49.0 
III 13 18.6 26.5 75.5 
IV 12 17.1 24.5 100.0 
Total 49 70.0 100.0   
Missing System 21 30.0     
Total 70 100.0     
 
FIGURE 7.3 PIE CHART SHOWING GOLD STAGE DESTRIBUTION IN 
STUDY GROUP 
 
 
 
 
 
 
12% 
37% 
27% 
24% 
Gold Stage 
I II III IV
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7.4 GROUP STATISTICS 
TABLE 7.4 T-TEST 
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TABLE 7.5: INDEPENDENT SAMPLES TEST 
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TABLE 7.6: DESCRIPTIVES 
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TABLE 7.7: ANOVA 
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TABLE 7.8: POST HOC TESTS- MULTIPLE COMPARISONS 
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70 
 
71 
 
 
72 
 
 
73 
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TABLE 7.9: CORRELATION 
 
Correlations 
  FEV1 FEV1/FVC 
Pearson 
Correlation 
Sig. (2-
tailed) 
Pearson 
Correlation 
Sig. (2-
tailed) 
FEV1/FVC .820 .005   
% LUNG ATTENUATION<-
950HU 
-.813 .005 -.697 .005 
MLAI .868 .005 .753 .005 
% LUNG ATTENUATION<-
856 HU 
-.934 .005 -.799 .005 
MLAE .836 .005 .739 .005 
INNER DIAMETER (mm) .868 .005 .751 .005 
AWWT -.668 .005 -.584 .005 
INNER AREA (mm2) .875 .005 .759 .005 
OUTER AREA (mm2) .667 .005 .574 .005 
WALL AREA (mm2) -.018 .884 -.022 .854 
 
TABLE 7.10: COEFFICIENTS 
Coefficients
a
 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 95.0% 
Confidence 
Interval for B 
B Std. 
Error 
Beta Lower 
Bound 
Upper 
Bound 
  (Constant) .522 .277   1.887 .064 -.030 1.074 
LUNG < -
950 % 
-.005 .002 -.171 -2.094 .040 -.009 .000 
LUNG < -
856 % 
-.011 .001 -.848 -8.201 .005 -.013 -.008 
INNER 
DIAMETER 
(mm) 
-.015 .063 -.024 -.231 .818 -.141 .112 
AWWT .031 .089 .015 .350 .728 -.147 .210 
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CROSSTABULATION – HOMOGENOUS SUBSETS 
TABLE 7.11: FEV1 
FEV1 
Tukey HSD 
GOLD STAGE N 
Subset for alpha = 0.05 
1 2 3 4 
Stage IV 12 .5708       
Stage III 13 .8146 .8146     
Stage II 18   1.1378 1.1378   
Stage I 6     1.3833   
Control 21       3.3571 
Sig.   .265 .067 .258 1.000 
 
 
 
TABLE 7.12:FVC      
FVC 
 Tukey HSD 
 
GOLD STAGE N 
Subset for alpha = 0.05 
 1 2 3 
 Stage IV 12 .9425     
 Stage III 13 1.2854     
 Stage II 18   1.7611   
 Stage I 6   2.1800   
 Control 21     4.0714 
 Sig.   .216 .079 1.000 
  
  
  
TABLE 7.13: FEV1/FVC 
 
 FEV1/FVC 
   Tukey HSD 
   
GOLD STAGE N 
Subset for alpha = 
0.05 
   1 2 
   Stage IV 12 .6100   
   Stage III 13 .6377   
   Stage I 6 .6417   
   Stage II 18 .6483   
   Control 21   .8252 
   Sig.   .459 1.000 
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TABLE 7.14: % LUNG ATTENUATION < -950 
    
 
       
% Of Lung Attenuation <-950HU 
Tukey HSD 
GOLD STAGE N 
Subset for alpha = 0.05 
1 2 3 4 5 
Control 21 .090         
Stage I 6   6.233       
Stage II 18     9.683     
Stage III 13       17.954   
Stage IV 12         29.725 
Sig.   1.000 1.000 1.000 1.000 1.000 
 
 
TABLE 7.15: Mean Lung Attenuation in Inspiration(MLAI) 
 
 
       
Mean Lung Attenuation in Inspiration(MLAI) 
 Tukey HSD 
 
GOLD STAGE N 
Subset for alpha = 0.05 
 1 2 3 4 
 Stage IV 12 -889.42       
 Stage III 13 -882.85 -882.85     
 Stage II 18   -867.89     
 Stage I 6     -849.00   
 Control 21       -818.33 
 Sig.   .798 .094 1.000 1.000 
  
  
 TABLE 7.16: TLC (L) 
TLC (L) 
  Tukey HSD 
  
GOLD STAGE N 
Subset for alpha = 0.05 
  1 2 3 
  Control 21 4.538     
  Stage I 6   5.217   
  Stage II 18   5.233   
  Stage III 13   5.392 5.392 
  Stage IV 12     5.833 
  Sig.   1.000 .814 .062 
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TABLE 7.17: % LUNG ATTENUATION <-856 HU 
   
  
       % Lung Attenuation <-856 HU 
Tukey HSD 
GOLD STAGE N 
Subset for alpha = 0.05 
1 2 3 4 5 
Control 21 .443         
Stage I 6   21.717       
Stage II 18     39.667     
Stage III 13       50.777   
Stage IV 12         60.658 
Sig.   1.000 1.000 1.000 1.000 1.000 
 
 
TABLE 7.18 : MEAN LUNG ATTENUATION IN EXPIRATION 
 
 
                     Mean Lung Attenuation in 
Expiration(MLAE) 
    Tukey HSD 
GOLD STAGE N 
Subset for alpha = 0.05 
1 2 3 4 5 
Stage IV 12 -846.25         
Stage III 13   -806.15       
Stage II 18     -765.00     
Stage I 6       -734.17   
Control 21         -706.71 
Sig.   1.000 1.000 1.000 1.000 1.000 
 
 
 
TABLE 7.19: FRC(L) 
FRC (L) 
  Tukey HSD 
  
GOLD STAGE N 
Subset for alpha = 0.05 
  1 2 3 
  Control 21 2.414     
  Stage I 6   3.033   
  Stage II 18   3.172   
  Stage III 13   3.408 3.408 
  Stage IV 12     3.775 
  Sig.   1.000 .060 .068 
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Table 7.20: INNER DIAMETER (mm) 
    
     Inner Diameter (mm) 
Tukey HSD 
GOLD STAGE N 
Subset for alpha = 0.05 
1 2 3 4 5 
Stage IV 12 2.842         
Stage III 13   3.146       
Stage II 18     3.433     
Stage I 6       3.733   
Control 21         4.110 
Sig.   1.000 1.000 1.000 1.000 1.000 
 
 
TABLE 7.21: AIRWAY WALL THICKNESS(AWWT) 
 
       Airway Wall Thickness(AWWT) 
  Tukey HSD 
  
GOLD STAGE N 
Subset for alpha = 0.05 
  1 2 3 
  Control 21 1.300     
  Stage I 6   1.417   
  Stage II 18   1.461   
  Stage III 13   1.485   
  Stage IV 12     1.600 
  Sig.   1.000 .428 1.000 
   
 
TABLE 7.22:  INNER AREA (mm2) 
   
  Inner Area (mm2) 
Tukey HSD 
GOLD STAGE N 
Subset for alpha = 0.05 
1 2 3 4 5 
Stage IV 12 6.325         
Stage III 13   7.731       
Stage II 18     9.211     
Stage I 6       10.467   
Control 21         13.257 
Sig.   1.000 1.000 1.000 1.000 1.000 
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TABLE 7.23: OUTER AREA (mm2) 
 
 
      Outer Area (mm2) 
 Tukey HSD 
 
GOLD STAGE N 
Subset for alpha = 0.05 
 1 2 3 4 
 Stage IV 12 28.700       
 Stage III 13 29.415 29.415     
 Stage II 18   31.772 31.772   
 Stage I 6     33.867 33.867 
 Control 21       35.395 
 Sig.   .953 .145 .241 .554 
  
 
 
TABLE 7.24: WALL AREA (mm2) 
  
 Wall Area (mm2) 
    Tukey HSD 
    
GOLD STAGE N 
Subset 
for 
alpha = 
0.05 
    1 
    Stage III 13 21.685 
    Control 21 22.114 
    Stage IV 12 22.375 
    Stage II 18 22.561 
    Stage I 6 23.400 
    Sig.   .263 
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RESULTS: 
 
1. Among the 70 subjects studied, 21 subjects without COPD (no spirometric 
evidence of airway obstruction) served as control and 49 cases with COPD 
served as cases.  
2. The study group consisted of 6 subjects with GOLD stage 1 disease (12%), 18 
subjects with GOLD stage 2 disease (37%), 13 subjects with GOLD stage 3 
disease (27%), and 12 subjects with GOLD stage 4 disease (24%).  
3. The cohort consists of 57 men (81%) and 13 women (19%). 
In the 49 subjects with COPD, 
 Progressively increasing LAA-950I (Low attenuation area in Inspiration <-
950HU) and LAA856E (Low attenuation areas in Expiration <-856HU) were 
noted for increasing GOLD stage and COPD disease severity.  
 Mean LAA-950I and LAA856E values progressively increased with increasing 
GOLD stage (p < 0.005). 
 For air trapping, LAA-856E showed correlation for both FEV1 and FEV1/FVC 
(r = –0.93 and –0.79, respectively) (Figure 7.6 & 7.7).  
 Emphysema showed similar results, with LAA-950I showing correlation for 
FEV1 and FEV1/FVC (r = –0.81 and –0.69, respectively) (Figure 7.4 & 7.5).  
 Other measures, such as the difference in mean lung attenuation, showed very 
high correlation with spirometric measures also. 
 Both TLC and FRC increase across GOLD stage. 
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 airway wall thickness, inner area, inner diameter and outer area showed 
good correlation to both FEV1 and FEV1/FVC for all subjects in the 
cohort. 
 Measures of wall area showed poor correlation to both FEV1 (r -.01) and 
FEV1/FVC (r -.02) 
 
 
FIGURE 7.4: Scatterplot shows percentage of low-attenuation areas ≤ –950 HU on 
inspiratory CT (LAA-950I) and forced expiratory volume in 1 second (FEV1). Line 
shows linear correlation. 
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FIGURE 7.5: Scatterplot shows LAA-950I and ratio of FEV1 to forced vital capacity 
(FVC). Line shows linear correlation. 
 
FIGURE 7.6: Scatterplot shows percentage of low-attenuation areas ≤ –856 HU on 
expiratory CT (LAA-856E)and FEV1 . Line shows linear correlation. 
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FIGURE 7.7: Scatterplot shows LAA-856E and FEV1 /FVC ratio. Line shows linear 
correlation. 
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8.DISCUSSION 
The potential usefulness of CT for identification of regions of pulmonary emphysema 
and air trapping has been addressed in many investigations
[72-74]
.. Several lung 
attenuation parameters have been developed based on results of histogram analysis of 
the frequency distribution of the attenuation values of the lung, to objectively quantify 
pulmonary emphysema with CT. 
The purpose of our study was to determine whether measurements of lung attenuation 
obtained from 3D lung reconstructions at inspiration and expiration reflect the severity 
of chronic obstructive pulmonary disease (COPD). We correlated lung function 
measurements at inspiration and expiration with measurements of lung attenuation on 
3D lung reconstructions. We also evaluated the relationship between severity of 
COPD, reflected by GOLD staging
[1]
, and measurements of lung attenuation on 3D 
lung reconstructions. 
Among the 70 subjects studied, 21 subjects without COPD (no spirometric evidence 
of airway obstruction) served as control and 49 subjects with COPD served as cases.  
The study group consisted of 6 subjects with GOLD stage 1 disease (12%), 18 
subjects with GOLD stage 2 disease (37%), 13 subjects with GOLD stage 3 disease 
(27%), and 12 subjects with GOLD stage 4 disease (24%).  
The cohort consists of 57 men (81%) and 13 women (19%). 
The results of this investigation show that QCT assessments of inspiratory and 
expiratory low-attenuation areas correlate with airflow obstruction assessed by 
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measures of FEV1 and FEV1/FVC and that these parameters increase in severity with 
increasing GOLD stage.  Statistical analysis suggests that CT-determined LAA-856E 
is strongly associated with decline in airflow in patients with COPD. CT is uniquely 
able to detect, classify, and quantify LAA-950I in adults. The quantitative assessment 
of low-attenuation areas is based on determining the percentage of lung pixels that are 
below –950 HU (ie, density mask technique)[66,68,69].  
Madani et al.
[66]
reported that the best correlation between QCT and macroscopic and 
microscopic measures of emphysema was obtained using a density mask technique 
with a threshold level of –960 or –970 HU, although the correlation for a threshold of 
–950 HU was almost as high. Because of concerns that a threshold of –960 or –970 
HU might exclude milder degrees of emphysema, we selected a threshold of –950 HU 
for the purposes of this study. 
In subjects with severe asthma, Busacker et al.
[75]
 used a threshold for assessing air 
trapping of –850 HU on chest CT scans obtained at FRC. The selection of –856 HU as 
the threshold for air trapping on expiratory CT is based on the fact that –856 HU is the 
mean attenuation of normally inflated lung (≈ 6 mL air per gram of lung) on 
inspiration. Therefore, in a normal lung, the attenuation should be higher than –856 
HU on expiration. The results of our study confirm that there is a strong relationship 
between air trapping measured on expiratory CT and expiratory airflow obstruction 
assessed by FEV1 and FEV1/FVC ratio; these findings suggest that this measure 
provides a robust independent measure of airflow obstruction.  
Hasegawa et al
[68]
reported that measurements of the bronchial wall area and inner 
luminal area obtained in distal (small) airways were more closely correlated with the 
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percentage of predicted FEV1 than those obtained in proximal (large) airways. These 
findings may indicate that airflow limitation is more closely related to the dimensions 
of the small airways than to those of the large airways. 
At the segmental (fourth-generation) airway level, there is modest correlation between 
functional or density measures and available airway measures. Measurement beyond 
the subsegmental level, however, is limited by CT spatial resolution and is highly 
dependent on CT scanner and protocol parameters. Han et al.
[76] 
have shown that 
airway wall measurements may be useful for predicting acute exacerbations of COPD.  
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9.LIMITATIONS OF STUDY: 
Our study was associated with multiple limitations. 
 The CT attenuation values are affected by variation in inspiratory and 
expiratory lung volumes and acquisition techniques.  
 Limited number of study subjects (70). 
 Poor breath holding by subjects affected the correct measurement of lung 
volumes (TLC & ERC).  
 Manual measurement of 4th generation segmental bronchial measurements. 
 Full-body plethysmography was not performed as part of this study; hence, 
measures such as the diffusion capacity of lung for carbon monoxide and true 
TLC could not be determined.  
 
 
 
 
 
 
 
 
 
88 
 
10. CONCLUSION: 
We conclude that QCT measurements of inspiratory and expiratory low-attenuation 
areas are strongly associated with spirometric impairment in subjects with COPD.  
QCT of the lung parenchyma uses accurate measures of lung density to generate 
histogram statistics of the lung to detect lower-density areas of the lung that 
correspond to emphysema on total lung capacity (TLC) scans and can also look at 
lower-density areas of the lung that correspond to air trapping on CT scans of the lung 
obtained at functional residual capacity (FRC) or residual volume(RV). The detection 
of the emphysema is a direct measure of lung remodeling in COPD, and the detection 
of air trapping is an indirect measure of small airway disease. 
Although univariate correlation between airway measures and spirometric impairment 
is less strong, inclusion of these measures in the multiple regression model strengthens 
the correlation.  
Air trapping on expiratory imaging measured as LAA-856E strongly correlates with 
physiologic measurements of airway obstruction. 
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ABBREVIATIONS 
COPD  : Chronic Obstructive Pulmonary Disease 
GOLD  : Global Initiative for Chronic Obstructive Lung Disease 
HRCT  : High-resolution computed tomography 
QCT  : Quantitative CT 
PFT  : Pulmonary Function Test 
TLC  : Total Lung Capacity 
FRC  : Functional Residual Capacity 
RV  : Residual Volume 
FEV1  : Forced Expiratory Volume (volume of air removed in first 
second) 
FVC  : Forced Vital Capacity (total volume of air removed during 
forceful expiration after maximal inhalation) 
VEGF  : Vascular endothelial growth factor 
HU  : Hounsfield unit 
MLAI  : Mean Lung Attenuation in Inspiration 
MLAE  : Mean Lung Attenuation in Expiration 
AWWT  : Airway Wall Thickness 
LAA-950I  : Low attenuation area in Inspiration <-950HU 
LAA856E  : Low attenuation areas in Expiration <-856HU 
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NAME: 
AGE: 
SEX: 
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PFT VALUES 
FEV1  
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FEV1/FVC  
 
 
 
 
 
 
QCT  VALUES 
Inspiratory CT 
   % Lung pixels ≤ –950HU 
    Mean lung attenuation (HU) 
    TLC(CT) 
 
Expiratory CT 
   % Lung pixels ≤ –856HU 
    Mean lung attenuation (HU) 
   FRC(CT) 
 
Airway 
   Inner diameter (mm) 
   Airway wall thickness (mm) 
   Outer area (mm2) 
   Inner area (mm2) 
   Wall area (mm2) 
    
 
 
 
 
 
 
 
 
PATIENT INFORMATION SHEET 
 
“ROLE OF QUANTITATIVE CT IN COPD & ITS CORRELATION WITH 
PULMONARY FUNCTION TEST VALUES” 
 
 Your cooperation would be valuable to us for the same 
 The privacy of patients in the research will be maintained throughout the study. 
In the event of any publication or presentation resulting from the research, no 
personally identifiable information will be shared. 
 Taking part of the study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time. Your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 The result of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
Signature of the investigator                                       Signature of participant 
 
Date: 
  
PATIENT CONSENT FORM 
“ROLE OF QUANTITATIVE CT IN COPD & ITS CORRELATION WITH 
PULMONARY FUNCTION TEST VALUES” 
       
PARTICIPANT’SNAME:  
AGE:                        
SEX:                     
OP/IP.NO. : 
 
  I confirm that I have understood the purpose of procedure for the above 
study.I have the opportunity to ask the questions and all my questions and doubts have 
been answered to my satisfaction. 
 I have been explained about the pitfall in the procedure.I have been explained 
about the safety,advantage and disadvantage of the technique.  
I understand that my participation in the study is voluntary and that I’m free to 
withdraw at any time without giving any reason. 
 I understand that investigator,regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to current 
study and any further research that may be conducted in relation to it,even if I 
withdraw from the study. 
I understand that my identity will not be revealed in any information released 
to third parties or published,unless as required under the law.I agree not to restrict the 
use of any data or results that arise from the study. 
I HEREBY CONSENT TO UNDERGO COMPLETE PHYSICAL 
EXAMINATION, BIOCHEMICAL AND RADIOLOGICAL INVESTIGATION 
PERTAINING TO THE STUDY. 
 
 
Signature/Thumb Impression of Participant 
 
MASTER CHART : CASES 
S. 
NO 
SEX 
AGE  
(yrs) 
FEV1 FVC 
FEV1/ 
FVC 
GOLD  
STAGE 
% OF  
LUNG  
<-950HU 
MEAN LUNG  
ATTENUATION  
(INSPIRATION) HU 
TLC  
(L) 
% LUNG  
<-856 HU 
MEAN LUNG  
ATTENUATION  
(EXPIRATION)  
HU 
FRC  
(L) 
INNER  
DIAMETER  
(mm) 
AIRWAY  
WALL  
THICKNESS  
(mm) 
INNER  
AREA  
(mm2) 
OUTER  
AREA  
(mm2) 
WALL  
AREA  
(mm2) 
1 M 45 1.41 2.1 0.7 1 5.8 -855 5.2 15.7 -741 2.9 3.8 1.5 11.3 36.3 25 
2 M 51 1.33 1.8 0.7 1 5.4 -843 5.3 25.3 -733 3.1 3.6 1.4 7.5 32.1 25 
3 M 49 1.5 2.5 0.6 1 6.6 -848 5.1 18.6 -725 3 3.7 1.4 10.7 33.1 22 
4 M 58 1.34 2.5 0.5 1 7.3 -850 5.2 20.8 -738 3.2 3.8 1.4 11.3 34.2 23 
5 M 55 1.42 2.3 0.6 1 5.6 -833 5.2 22.5 -723 3.1 3.8 1.5 11.3 36.3 25 
6 M 47 1.3 1.8 0.7 1 6.7 -865 5.3 27.4 -745 2.9 3.7 1.3 10.7 31.2 21 
7 M 45 1.15 1.8 0.7 2 9.5 -873 5.5 38.2 -767 3.3 3.6 1.5 10.1 34.2 24 
8 M 48 1.26 2.3 0.6 2 8.8 -868 5.4 46.5 -789 3.2 3.5 1.5 9.6 33.2 24 
9 M 52 1.22 2 0.6 2 11 -875 5.4 37.8 -758 3.3 3.6 1.6 10.1 36.3 26 
10 M 59 1.18 1.8 0.7 2 11 -854 5.4 33.7 -770 3.4 3.4 1.4 9 30.2 21 
11 M 46 1.12 1.6 0.7 2 9.7 -880 5.5 42.6 -752 3.4 3.3 1.5 8.5 31.1 23 
12 M 61 1.1 1.5 0.7 2 10 -865 5.3 35.5 -744 3.3 3.5 1.5 9.6 33.2 24 
13 M 53 1.26 1.9 0.7 2 8.6 -872 5.4 43.2 -785 3.2 3.4 1.6 9 34.2 25 
14 M 57 1.05 1.9 0.5 2 12 -878 5.5 39.4 -764 3.3 3.4 1.3 9 28.3 19 
15 M 62 1 1.6 0.6 2 10 -864 5.4 36.7 -792 3.4 3.3 1.4 8.5 29.2 21 
16 M 48 1.11 1.6 0.7 2 9.8 -884 5.3 42.1 -742 3.2 3.4 1.6 9 34.2 25 
17 M 54 1.03 1.6 0.6 2 8.5 -857 5.3 43.1 -755 3.3 3.5 1.6 9.6 35.2 26 
18 M 57 1.25 2.2 0.6 2 10 -862 5.3 40.4 -763 3.4 3.3 1.3 8.5 27.3 19 
19 M 46 1.2 2 0.6 2 8.7 -876 5.5 38.4 -778 3.4 3.3 1.4 8.5 29.2 21 
20 M 60 1.13 1.6 0.7 2 9.3 -871 5.4 35.6 -750 3.3 3.4 1.5 9 32.2 23 
21 M 55 1 1.5 0.7 2 9.6 -860 5.4 42.8 -774 3.2 3.5 1.4 9.6 31.2 22 
22 M 49 0.77 1.1 0.7 3 18 -886 5.6 48.4 -805 3.8 3.2 1.3 8 26.4 18 
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25 M 53 0.9 1.4 0.6 3 19 -879 5.7 49.6 -817 3.6 3 1.4 7 26.4 19 
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28 M 50 0.82 1.5 0.5 3 17 -878 5.7 48.6 -817 3.5 3.1 1.5 7.5 29.2 22 
29 M 54 0.79 1.2 0.6 3 19 -888 5.8 52.5 -805 3.6 3.1 1.6 7.5 31.2 24 
30 M 49 0.73 1.1 0.7 3 16 -893 5.9 50.6 -799 3.8 3 1.3 7 24.6 18 
31 M 51 0.6 1.2 0.5 4 27 -887 6.1 57.8 -867 3.8 3 1.6 7 30.2 23 
32 M 46 0.58 1.1 0.5 4 30 -894 5.9 60.1 -822 4 2.9 1.7 6.6 31.2 25 
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38 M 60 0.62 0.9 0.7 4 29 -876 5.9 65.2 -850 4.1 2.7 1.6 5.7 27.3 22 
39 M 45 0.5 0.8 0.6 4 34 -900 5.8 59.5 -863 3.9 2.9 1.7 6.6 31.2 25 
40 M 53 0.65 1.1 0.6 4 32 -883 6.2 64.3 -843 3.9 2.7 1.6 5.7 27.3 22 
41 F 46 1.14 1.6 0.7 2 10 -867 4.4 37.9 -765 2.6 3.5 1.4 9.6 31.2 22 
42 F 50 1.26 1.8 0.7 2 7.8 -852 4.5 40.6 -752 2.5 3.4 1.3 9 28.3 19 
43 F 48 1.02 1.5 0.7 2 9.5 -864 4.3 39.5 -770 2.4 3.5 1.5 9.6 33.2 24 
44 F 53 0.82 1.4 0.6 3 18 -870 4.5 48.3 -806 2.8 3.3 1.4 8.5 29.2 21 
45 F 57 0.94 1.6 0.6 3 21 -878 4.6 52.7 -789 2.7 3.1 1.5 7.5 29.2 22 
46 F 45 0.75 1.1 0.7 3 20 -867 4.6 50.5 -796 2.8 3.2 1.5 8 30.2 22 
47 F 47 0.78 1.1 0.7 3 18 -873 4.8 51.8 -810 2.8 3.2 1.6 8 32.2 24 
48 F 51 0.55 1 0.6 4 33 -895 5 60.4 -857 3 2.9 1.4 6.6 25.5 19 
49 F 46 0.67 1.1 0.6 4 29 -888 4.9 64.8 -822 2.9 3 1.6 7 30.2 23 
 
  
MASTER CHART: CONTROLS 
SEX 
AGE 
(yrs) 
FEV1 FVC FEV1/FVC 
% OF  
LUNG  
<-950HU 
MEAN  
LUNG  
ATTENUATION 
TLC  
(ml) 
% LUNG  
<-856 HU 
MEAN  
LUNG  
ATTENUATION 
FRC 
INNER  
DIAMETER  
(mm) 
AIRWAY  
WALL  
THICKNESS  
(mm) 
INNER  
AREA  
(mm2) 
OUTER  
AREA  
(mm2) 
WALL  
AREA 
M 49 3.7 5 0.8 0 812 4.5 0.1 708 2.3 4.3 1.2 15 35.2 20.7 
M 45 3 4 0.83 0 826 4.7 0 697 2.5 4.4 1.4 15 40.7 25.5 
M 51 3.8 4 0.9 0 810 4.5 0 701 2.4 4.2 1.3 14 36.3 22.5 
M 45 2.7 3 0.82 0 816 4.4 0.2 712 2.5 4.1 1.4 13 37.4 24.2 
M 41 2.2 2 0.95 0 830 4.7 0 689 2.5 4.4 1.2 15 36.3 21.1 
M 43 3.7 4 0.88 0 812 5.2 0 692 2.8 4 1.3 13 34.2 21.6 
M 47 3.6 4 0.84 0 800 4.5 0.1 708 2.2 4.2 1.4 14 38.5 24.6 
M 41 3.3 4 0.8 0 813 4.9 0 695 2.8 4.2 1.2 14 34.2 20.4 
M 56 3 4 0.78 0.1 853 4.6 0.5 707 2.5 4.1 1.4 13 37.4 24.2 
M 60 3.8 5 0.81 0 790 4.8 0.3 710 2.2 3.9 1.3 12 33.2 21.3 
M 58 2.7 3 0.8 0 793 4.8 0.6 700 2.7 4.2 1.2 14 34.2 20.4 
M 44 3.2 4 0.83 0 807 4.6 0 685 2.5 4.1 1.1 13 31.2 18 
M 43 4.1 5 0.87 0 811 4.4 0 705 2.2 4 1.3 13 34.2 21.7 
M 46 2.9 4 0.8 0 795 4.5 0 711 2.3 4.3 1.3 15 37.4 22.9 
M 52 4.3 5 0.84 0 828 4.6 0.2 694 2.4 4.4 1.4 15 40.7 25.5 
M 57 3.2 4 0.75 1 885 4.8 3.4 734 2.7 4.1 1.2 13 33.2 20 
M 48 3.4 5 0.77 0.5 824 4.4 1.8 722 2.2 3.9 1.3 12 33.2 21.2 
F 44 3.2 4 0.79 0.3 840 4.1 1.2 728 2.1 3.8 1.4 11 34.2 22.8 
F 47 3.5 4 0.8 0 814 4 0.3 720 2 4 1.3 13 34.2 21.7 
F 42 3.9 5 0.85 0 821 4.2 0 707 2.7 3.9 1.3 12 33.2 21.3 
F 40 3.3 4 0.82 0 805 4.1 0.6 716 2.2 3.8 1.4 11 34.2 22.8 
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